Zenith Drugs

When is the next results date for Zenith?

No Upcoming Board Meetings

Has Zenith declared dividend?

Zenith Drugs Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 17, 2024. While the dividend yield is 0.73%, total returns have varied significantly, showing a -22.92% return over the last 6 months and a modest 9.75% return over the past year.

Zenith Drugs Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 17 Sep 24<BR><BR>Dividend Yield: 0.73%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.92%, the dividend return was 0%, resulting in a total return of -22.92%.<BR><BR>Over the past year, the price return was 8.98%, the dividend return was 0.77%, leading to a total return of 9.75%.<BR><BR>For the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>Over the last 4 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>For the 5-year period, the price return and dividend return were both 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Zenith has declared a dividend, the total returns over various periods show mixed results, with significant negative returns in the short term and modest positive returns in the longer term. The dividend yield is relatively low, indicating that while dividends are being paid, the overall performance may not be strong.

Who are the peers of the Zenith?

Zenith's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Parnax Lab, Mangalam Drugs, Welcure Drugs, Source Natural, and Samrat Pharma. Management risk and growth vary among peers, with Sun Pharma and Cipla showing excellent metrics, while Welcure Drugs has the highest 1-year return at 146.68% and Mangalam Drugs the lowest at -18.62%.

Peers: The peers of Zenith are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Parnax Lab, Mangalam Drugs, Welcure Drugs, Source Natural, and Samrat Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Source Natural, and Samrat Pharma, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Below Average management risk is noted at Parnax Lab, Welcure Drugs, and the rest, while Average management risk is seen at Mangalam Drugs. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is found at Divi's Lab., Torrent Pharma, Source Natural, and Samrat Pharma, with Good growth at Parnax Lab. Below Average growth is also noted for Mangalam Drugs and Welcure Drugs. Capital Structure is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Divi's Lab., and Parnax Lab, while Good capital structure is found at Torrent Pharma and Samrat Pharma, Average at Zenith, and Below Average at Mangalam Drugs and Welcure Drugs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Welcure Drugs at 146.68%, while the lowest is Mangalam Drugs at -18.62%. Zenith's own 1-year return is 0.00%, which is lower than Welcure Drugs and higher than Mangalam Drugs. Additionally, the six-month return is negative for Parnax Lab, Mangalam Drugs, and Samrat Pharma.

What is the technical trend for Zenith?

As of May 30, 2025, Zenith's technical trend has shifted to mildly bearish, supported by bearish signals from the MACD, moving averages, and Dow Theory, despite a conflicting bullish KST signal.

As of 30 May 2025, the technical trend for Zenith has changed from sideways to mildly bearish. The weekly MACD is bearish, and the daily moving averages also indicate a bearish stance. The Dow Theory confirms a mildly bearish outlook on both weekly and monthly time frames. Although the KST shows a bullish signal on the weekly, the overall sentiment is dampened by the bearish signals from the Bollinger Bands and the OBV, which is mildly bearish on the weekly but bullish on the monthly. The stock has underperformed significantly against the Sensex over the past month and year-to-date, further reinforcing the bearish sentiment.

What does Zenith Drugs do?

Zenith Drugs Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, recently converted to a Public Limited Company. It has no reported sales or profit for the latest quarter, with a market cap of INR 120 Cr.

Overview:<BR>Zenith Drugs Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Zenith Drugs Ltd was originally incorporated on November 15, 2000, as a Private Limited Company under the name "Zenith Drugs Private Limited." The company later converted to a Public Limited Company and changed its name to "Zenith Drugs Limited" following the issuance of a Fresh Certificate of Incorporation on September 13, 2023. There is no sales or profit data reported for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 120 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 17.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.69%<BR>Debt-Equity: 0.24<BR>Return on Equity: 11.51%<BR>Price-to-Book: 2.00<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the top shareholders of the Zenith Drugs?

The top shareholders of Zenith Drugs include promoter Ajay Singh Dassundi with 22.52%, individual investors with 25.56%, and public shareholder Praveen Mudunuri at 1.21%. There are also two foreign institutional investors holding 0.06%, and no mutual funds are currently invested in the company.

The top shareholders of Zenith Drugs include the promoters, who hold the majority of the shares. The promoter with the highest holding is Ajay Singh Dassundi, owning 22.52% of the company. Additionally, individual investors collectively hold 25.56% of the shares. In terms of institutional investors, there are two foreign institutional investors (FIIs) that hold a small portion, specifically 0.06%. The highest public shareholder is Praveen Mudunuri, with a holding of 1.21%. There are no mutual funds currently holding shares in the company.

How big is Zenith Drugs?

As of 23rd July, Zenith Drugs Ltd has a market capitalization of 122.00 Cr, classifying it as a Micro Cap company. Recent financial data for Net Sales and Net Profit is unavailable, with Shareholder's Funds at 62.26 Cr and Total Assets at 134.97 Cr as of March 2024.

As of 23rd July, <BR><BR>Market Cap: Zenith Drugs Ltd has a market capitalization of 122.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 62.26 Cr and Total Assets totaling 134.97 Cr.

How has been the historical performance of Zenith Drugs?

Zenith Drugs has shown significant growth over the past three years, with net sales increasing from 91.66 Cr in March 2022 to 131.62 Cr in March 2024, and operating profit rising from 7.85 Cr to 19.03 Cr. Despite negative cash flow from operations, the company has expanded its asset base and achieved strong profitability improvements.

Answer:<BR>The historical performance of Zenith Drugs shows significant growth over the past three years, particularly in revenue and profitability.<BR><BR>Breakdown:<BR>Zenith Drugs has experienced a steady increase in net sales, rising from 91.66 Cr in March 2022 to 114.52 Cr in March 2023, and further to 131.62 Cr in March 2024. Total operating income has mirrored this trend, reaching 131.62 Cr in March 2024. The company's total expenditure has also increased, from 84.82 Cr in March 2022 to 114.71 Cr in March 2024. However, operating profit (PBDIT) has shown a remarkable improvement, climbing from 7.85 Cr in March 2022 to 19.03 Cr in March 2024, indicating enhanced operational efficiency. Profit before tax has similarly surged from 4.41 Cr in March 2022 to 14.74 Cr in March 2024, while profit after tax has increased from 3.13 Cr to 10.94 Cr over the same period. The company's total assets have grown significantly, from 68.58 Cr in March 2022 to 134.97 Cr in March 2024, reflecting a robust expansion strategy. Cash flow from operating activities has been negative in recent years, but cash flow from investing activities turned positive in March 2024, contributing to a net cash inflow of 8.00 Cr. Overall, Zenith Drugs has demonstrated strong growth in sales and profitability, alongside an expanding asset base, despite challenges in cash flow from operations.

Is Zenith Drugs overvalued or undervalued?

As of November 18, 2025, Zenith Drugs is considered overvalued at a price of 57.35, with a PE ratio of 13.74 and a significant underperformance of -39.05% compared to the Sensex, especially when compared to its peers like Sun Pharma and Divi's Lab, which have much higher PE ratios.

As of 18 November 2025, Zenith Drugs has moved from a fair to an expensive valuation grade. The company appears to be overvalued at its current price of 57.35, especially when considering its PE ratio of 13.74, EV to EBIT of 14.11, and ROE of 9.98%. These metrics indicate that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Zenith Drugs' PE ratio is significantly lower than that of Sun Pharma (36.56) and Divi's Lab (69.17), which are both categorized as expensive to very expensive. Meanwhile, Cipla (22.49) and Dr. Reddy's Labs (17.97), which are rated attractive, have more favorable valuations. Additionally, Zenith Drugs has underperformed the Sensex significantly over the past year, with a stock return of -39.05% compared to the Sensex's 10.47%, reinforcing the notion that the stock is currently overvalued.

Why is Zenith Drugs Ltd falling/rising?

As of 06-Feb, Zenith Drugs Ltd's stock price is declining at 49.00, down 0.1%, and has significantly underperformed the Sensex, with a year-to-date drop of 2.39% compared to the Sensex's 1.67% decline. The stock's one-year performance is particularly poor, down 41.39%, alongside a notable decrease in investor participation.

As of 06-Feb, Zenith Drugs Ltd is experiencing a slight decline in its stock price, currently at 49.00, which reflects a change of -0.05 (-0.1%). This decline is part of a broader trend, as the stock has underperformed significantly compared to the benchmark Sensex over various periods. Over the past week, Zenith Drugs has decreased by 10.58%, while the Sensex has increased by 1.47%. In the last month, the stock has fallen by 4.30%, contrasting with a 1.85% decline in the Sensex.<BR><BR>Moreover, the stock's performance year-to-date shows a decrease of 2.39%, compared to a smaller decline of 1.67% in the Sensex. The one-year performance is particularly concerning, with Zenith Drugs down 41.39%, while the Sensex has gained 8.86%. The lack of positive momentum is further highlighted by the stock trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages.<BR><BR>Additionally, there has been a significant drop in investor participation, with delivery volume on February 5 falling by 83.05% against the 5-day average. This decline in trading activity suggests a lack of interest or confidence among investors, contributing to the stock's downward trajectory. Overall, these factors indicate that Zenith Drugs Ltd is currently facing challenges that are leading to its falling stock price.

Which are the latest news on Zenith Drugs?